BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

BACKGROUND: Although pazopanib treatment has become the standard chemotherapy in salvage setting for metastatic sarcoma patients, most patients progress after pazopanib treatment in 4 to 6 months. After failure to pazopanib, patients have limited options for treatment. Therefore, subsequent therapy...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Transl Oncol
Päätekijät: Kim, Hee Kyung, Kim, Sun Young, Lee, Su Jin, Kang, Mihyeon, Kim, Seung Tae, Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Lee, Dong Woo, Park, Woong Yang, Kim, Sung Joo, Park, Se Hoon, Lee, Jeeyun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Neoplasia Press 2016
Aiheet:
Original article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907899/
https://ncbi.nlm.nih.gov/pubmed/27267837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2016.03.008
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia